High hs-CRP and Your Heart: How to Lower Cardiac Inflammation

If you live in Chattanooga or Signal Mountain and your lab report just flagged a “high-sensitivity CRP,” you probably have two questions. Is my heart in trouble? And what do I do about it? I’m Paul Miranda, MD, and at Summit Metabolic Health I review every chart myself. This is the straight version of what the research says in 2026, including the parts that surprised cardiologists this summer.

C-reactive protein is made by your liver when the immune system signals inflammation, mostly through a messenger called interleukin-6 (IL-6). The “high-sensitivity” test picks up the low, smoldering levels linked to heart disease rather than the big spikes of an infection.

The usual cardiac ranges:

– Under 1 mg/L: lower risk – 1 to 3 mg/L: average risk – Over 3 mg/L: higher risk – Over 10 mg/L: usually a cold, an injury, or another acute problem. Repeat the test once you’re well.

Most heart trials use 2 mg/L or higher as the line for “residual inflammatory risk.” One reading isn’t enough. Check it twice, a couple of weeks apart, when you’re healthy.

The test has moved into the mainstream. A 2025 American College of Cardiology scientific statement in JACC called for routine hs-CRP testing in both prevention and established heart disease. The 2026 ACC/AHA cholesterol guideline lists an elevated hs-CRP as a “risk enhancer” that can tip a borderline patient toward treatment. In a pooled analysis of more than 31,000 patients already on statins, hs-CRP predicted future heart events and cardiovascular death more strongly than LDL cholesterol did.

One honest caveat. Genetic studies suggest CRP itself doesn’t cause heart disease. It’s the smoke, not the fire. The fire is the inflammatory pathway behind it. That distinction matters, as you’ll see below.

Weight loss. Fat tissue, especially belly fat, produces IL-6. A review of 33 studies found CRP fell about 0.13 mg/L for every kilogram (2.2 lb) lost. This is the biggest lever most of my patients have.

A Mediterranean-style diet. Across six trials, people on a Mediterranean diet had hs-CRP about 1.0 mg/L lower than people on low-fat diets after two years. Think olive oil, fish, beans, vegetables and nuts, with less processed food.

Movement. Exercise lowers heart risk on its own. Its CRP effect comes mostly through weight loss and fitness, so do it for your heart, not for the lab number.

Quitting smoking. CRP comes down slowly after you quit and can stay elevated for years, which is a reason to quit sooner, not a reason to skip it.

Sleep apnea. If you snore and wake up tired, get tested. In small studies, people who actually used their CPAP saw CRP fall.

Your gums. Gum disease is a quiet source of inflammation. Meta-analyses of 20 and 26 randomized trials found periodontal treatment lowered CRP by roughly 0.4 to 0.7 mg/L, with the biggest drops in people starting above 3.

Supplements. Omega-3s and curcumin each show modest CRP reductions in large pooled analyses. Those studies vary a lot, and none show fewer heart attacks from the CRP drop. They are reasonable add-ons, not a plan.

Statins. The JUPITER trial enrolled people with normal LDL but hs-CRP of 2 or higher. Rosuvastatin lowered hs-CRP 37% and cut heart attacks, strokes and related events by 44%. That trial is why an elevated hs-CRP can justify a statin even when cholesterol looks fine.

Bempedoic acid. For people who can’t take statins, it lowered hs-CRP about 22% in the CLEAR Outcomes trial. PCSK9 inhibitors, by contrast, drop LDL dramatically but barely move CRP. Cholesterol and inflammation are separate risks that need separate attention.

Low-dose colchicine. This old gout drug became the first anti-inflammatory approved by the FDA to reduce heart events (2023, at 0.5 mg daily), based on the LoDoCo2 trial in stable coronary disease, which showed a 31% reduction. The picture is mixed. CLEAR SYNERGY, a 7,062-patient trial in people who had just had a heart attack and a stent, found no benefit. Colchicine is a cardiology decision for people with established coronary disease, and it has drug interactions and GI side effects.

The IL-6 surprise. On July 31, 2026, Novo Nordisk reported topline results from ZEUS, a 6,300-patient trial of the IL-6 blocker ziltivekimab in people with heart disease, kidney disease and hs-CRP of 2 or higher. The drug lowered hs-CRP and IL-6 as designed. It did not reduce heart attacks, strokes or cardiovascular deaths. Serious infections were more common. Full data come later this year.

ZEUS is the most important lesson in this post. Lowering the CRP number is not the same as protecting your heart. What matters is lowering it with something that has also been shown to prevent events.

This is where the GLP-1 class stands out. It lowers inflammation and it has outcome data.

In the SELECT trial, more than 17,000 adults with heart disease and overweight but no diabetes took semaglutide 2.4 mg or placebo. Semaglutide cut major cardiovascular events by 20%, and it lowered hs-CRP about 38% versus placebo at two years. The CRP drop showed up early, before most of the weight came off, and appeared regardless of starting weight. When researchers accounted for the CRP change, it explained part of the heart benefit, not all of it. Semaglutide (Wegovy) is FDA-approved to reduce the risk of major cardiovascular events in adults with established heart disease and obesity or overweight. I covered the broader picture in how GLP-1 medications affect heart health.

For tirzepatide, a 2026 JACC analysis of the SURMOUNT-1 trial found hs-CRP fell about 37%, 47% and 55% at the 5, 10 and 15 mg doses after 72 weeks, with IL-6 down 25 to 30%. In SURPASS-CVOT, tirzepatide matched dulaglutide, an older GLP-1 with proven heart benefit, on heart outcomes in type 2 diabetes. It was not shown to be superior. If you’re weighing the two, see my semaglutide vs. tirzepatide comparison.

Newer agents studied in phase 3 trials, including oral orforglipron and the triple agonist retatrutide, reported hs-CRP reductions of roughly half. Those are biomarker results. Heart outcome data for both are still coming.

One practical point: losing weight on a GLP-1 means protecting muscle, which is its own metabolic organ. Here’s how we prevent muscle loss on semaglutide.

We don’t endorse, recommend, or sell unapproved peptides. A lot of people are asking about them, so here’s what you should know.

BPC-157, TB-500 (thymosin beta-4) and KPV are often marketed online as “anti-inflammatory.” I found no human trial that measured CRP for any of them. BPC-157’s human data amount to a few small studies with fewer than 30 people combined, none randomized. KPV has no human trials; its evidence is mostly in mice with colitis. None is FDA-approved, and products sold as “research peptides” have no guarantee of purity, dose or sterility.

The more promising “nontraditional” science is in drug development. A daily pill that blocks the NLRP3 inflammasome, an upstream inflammation switch, lowered hs-CRP 64% in a 175-person, 12-week phase 2 trial reported in 2025-2026. It is investigational, and after ZEUS, nobody should assume a big CRP drop means fewer heart attacks until an outcomes trial says so.

When a patient comes in with a high hs-CRP, here’s what I do:

1. Confirm it. Repeat the test when you’re well and rule out acute causes. 2. Put it in context. Pair it with LDL, ApoB, Lp(a), A1c and liver markers. Inflammation is one risk lane among several. 3. Find the driver. Excess weight, sleep apnea, gum disease, smoking and autoimmune conditions are the usual suspects. 4. Treat the driver. For many of our patients, that means a structured weight-loss plan, and a GLP-1 when it’s appropriate. 5. Coordinate. If you have heart disease or a borderline risk score, I work with your primary care doctor or cardiologist on statins or colchicine.

A high hs-CRP isn’t a diagnosis. It’s a signal worth acting on with treatments that have earned their place: weight loss, statins when indicated, and, for the right patient, a GLP-1 with heart-outcome data behind it. Ready to start? Apply at summitmetabolichealth.com/apply. You can find more physician-written guides on the Summit blog.

This post is educational and does not replace a one-on-one medical evaluation. Individual results vary. Peptides discussed here are not FDA-approved and are not prescribed or supplied by Summit. Dr. Paul Miranda is a physician practicing telehealth at Summit Metabolic Health in Chattanooga, TN.

– [[2026-10-08-hs-crp-cardiac-inflammation-reduction]] (research note, sources) – [[2026-09-03-glp1-anti-inflammatory-review]]